Innovent Biologics Showcases "Dual Innovations" at Oncology R&D Day, Pioneering the Future of Cancer Treatment with Next-Generation IO and ADC Platforms
'Over the past decade, Innovent has been at the forefront of China's biopharmaceutical evolution—pioneering the PD-1 immunotherapy era and building China's leading oncology brand, with over 3 million cancer patients treated with our therapies,' said Dr. Michael Yu, Founder, Chairman of the Board and CEO of Innovent. 'We are entering a new chapter focused on global innovation, powered by a robust pipeline and dual innovation of next-generation IO and next-generation ADC. Our recent presence at the 2025 ASCO with eight oral presentations highlights the strength and global competitiveness of our R&D. But this is only the beginning. With a clear vision to advance at least five pipeline assets into MRCT Phase 3 by 2030, we are committed to delivering innovative, high-quality, and accessible cancer treatments to patients worldwide.'
Dual Innovation to Unlock the Future of Oncology: Next-gen IO + Next-gen ADC
At the core of Innovent's oncology strategy lies the dual engines of next-generation immunotherapy (IO) and next-generation antibody-drug conjugates (ADC), supported by deep insights in cancer biology and differentiated technology platforms.
'We are harnessing deep cancer biology insights, advanced antibody and protein engineering, and differentiated ADC linker-payload technologies to develop broader-spectrum, more potent, and less toxic therapies aimed at transforming the oncology treatment paradigm,' said Dr. Zhou Hui, SVP of Innovent Oncology R&D. 'Our strategy is designed to target some of the toughest challenges in cancer care, including drug resistance, cold tumors, and improve the efficacy of current IO treatment, while bringing new hope to patients worldwide.'
Global R&D Roadmap: a Clear, Stepwise Development Strategy
Innovent's pipeline is guided by a rational, phased IO+ADC combination strategy designed to address tumor heterogeneity and immune escape, evolving through three stages:
Next-gen IO + Chemotherapy: to redefine the IO cornerstone
Next-gen IO + mAb-ADC / bispecific ADC: to cover expansive tumor types and treatment lines
Next-gen IO + Dual-Payload ADC (dpADC): to unlock full potential of IO+ ADC synergy, and reshape cancer treatment
Currently its oncology pipeline features nearly 10 next-generation molecules in global development, with multi-regional trials actively underway in the U.S., EU, and Asia. The company also continues to invest in global R&D infrastructure, supported by R&D hubs in Shanghai and San Francisco and antibody and ADC manufacturing capacity exceeding 140,000L.
Innovent is rapidly expanding its global innovation footprint, with a 2030 goal to advance at least five pipeline assets into global MRCT Phase 3 trials. Key potential candidates includes:
IBI343: innovative CLDN18.2 ADC with site-specific conjugation and a TOPO1 inhibitor payload, demonstrating significant survival benefits in both GC and PDAC
IBI363: PD-1/IL-2α-bias fusion protein as next-gen IO to redefine cancer treatment and expand the boundaries of IO responsiveness
IBI3009: DLL3 ADC in collaboration with Roche
IBI3003: tri-specific T-cell engager targeting BCMA/GPRC5D/CD3 for multiple myeloma
IBI3001: EGFR/B7H3 ADC with two synergetic targets covering multiple potential indications
IBI3020: CEACAM5 dual-payload ADC as globally the first to enter clinical phase
IBI363: Next-Gen IO Redefining Cancer Immunotherapy
IBI363 is a global first-in-class PD-1/IL-2α-bias fusion protein, featuring a differentiated molecular design and a dual immune activation mechanism. Emerging clinical data strongly support its mechanism of action in reinvigorating and expanding tumor-specific T cells (TSTs).
At ASCO 2025, IBI363 demonstrated breakthrough potential in three hard-to-treat tumor types, with a long tailing effect in prolonged survival benefits:
Immune-resistant NSCLC (squamous & Adeno): boosted response rate and extended PFS reflects strong immune activation; median overall survival (mOS) up to 17.5 months in 1.5 mg dose cohorts, 12-month OS rate exceeding 70% for 3 mg dose cohorts, and benefit observed even in PD-L1 low expressers
Later-line CRC (3L+): mOS of 16.1 months in monotherapy and only 17.8% OS events occurred in combination with bevacizumab with 9.4 months follow-up, outperforming historical benchmarks
Immune-resistant melanoma (mucosal/acral subtypes): confirmed overall response rate (cORR) 23%, median duration of response (mDoR) 14 months, and median OS 14.7 months, showing unprecedented positive response and a long-lasting immunologic tailing effect
With two Breakthrough Therapy Designations from the NMPA CDE, two Fast Track Designations from the FDA, IBI363 is advancing rapidly toward registrational development. The first head-to-head trial vs. pembrolizumab in mucosal and acral melanoma was initiated. Meanwhile, IBI363 is in preparation for registrational trails in IO-treated squamous NSCLC, and third-line MSS colorectal cancer. Additional trails for first-line and other solid tumors also under exploration in ongoing PoC studies.
High-Potency, Low-toxicity ADC Platforms Synergizing with IO for Broad Indication Coverage
Innovent is rapidly advancing its next-gen ADC pipeline, including:
IBI343 (CLDN18.2 ADC): first in PDAC to demonstrate long-term survival benefits (mOS 12.1 months in 2L)
IBI3001 (EGFR/B7H3 ADC): dual-targeted ADC with broad potential in solid tumors
IBI3020 (CEACAM5 dual payload ADC): designed for high efficacy and low toxicity in treatment-resistant tumors
These programs leverage proprietary payloads and linkers, optimized for lower toxicity and high potency, and are poised to synergize with Innovent's IO agents to address broader and deeper indications.
Innovent Academy: R&D Engine to Drive Global Innovation
Innovent Academy is the company's discovery engine for driving global innovation. The Academy continues to expand its platforms in IO, ADC, T-cell engagers, and cytokines, firmly establishing its leadership in next-gen oncology discovery and translational science to generate 6–8 novel molecules per year.
Specifically, for next-gen IO and next-gen ADC dual upgradation, Innovent Academy focuses on:
diversified antitumor mechanisms to integrate TME modulation and optimize IO efficacy;
dual targeting approaches to overcome tumor heterogeneity and drug resistance.
This framework allows Innovent to systematically escalate efficacy and broaden tumor applicability, laying the foundation for first-in-class and best-in-class combination regimens for cancer treatments.
Catalyzing China's Role in Global Oncology Innovation
Leading oncology KOLs and principal investigators (PIs) delivered keynote speeches, reflecting on a pivotal moment for China's biotech industry. They emphasized that China's innovation, which is driven by rising translational capabilities, expanding global talent pools, and patient-centric trial execution, has entered a 'Deepseek' moment, one where Chinese-discovered drugs can lead global standards, not just follow them.
'What we're witnessing is a profound shift,' said one keynote speaker. 'Innovent's next-generation IO programs like IBI363, with a clear global-first design, and ADC platforms targeting previously untreatable populations, show that Chinese biotech is poised to influence—not just participate in—the next global oncology paradigm.'
The enthusiastic response from investors and KOLs underscores growing confidence in China-originated oncology innovation and reaffirms Innovent's position as it enters a new era of global innovation with a vision to become a global premier biopharmaceutical leader.
About Innovent
Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 16 products in the market. It has 2 new drug applications (NDA) under regulatory review, 4 assets in Phase III or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center.
Guided by the motto, 'Start with Integrity, Succeed through Action,' Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.
Statement:
1) Innovent does not recommend the use of any unapproved drug (s)/indication (s).
2) Ramucirumab (Cyramza) and Selpercatinib (Retsevmo) and Pirtobrutinib (Jaypirca) were developed by Eli Lilly and Company.
Forward-Looking Statements
This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words 'anticipate', 'believe', 'estimate', 'expect', 'intend' and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly.
These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent's competitive environment and political, economic, legal and social conditions.
Innovent, the Directors and the employees of Innovent assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
2 hours ago
- Malaysian Reserve
In May, the Percentage of Patients with a Telehealth Claim Increased Nationally and in Every Region
Diabetes Entered Top Five Telehealth Diagnostic Categories in Midwest and West in May for First Time in 2025 NEW YORK, Aug. 15, 2025 /PRNewswire/ — In May 2025, the percentage of patients with a telehealth claim increased nationally and in all four US census regions, according to FAIR Health's Monthly Telehealth Regional Tracker. Nationally, that percentage increased from 14.2 percent of patients in April to 14.3 percent in May, a 0.8 percent rise. In May, the West had the largest share of patients with a telehealth claim, at 18.7 percent, and the Midwest had the smallest share, at 10.8 percent. The data represent the commercially insured population, excluding Medicare Fee-for-Service, Medicare Advantage and Medicaid. From April to May, changes in utilization as measured by telehealth claim lines1 varied. Nationally, telehealth claim lines fell from 5.01 percent of medical claim lines in April to 4.96 percent in May, a decrease of 1.0 percent. In the South, the decrease was 1.7 percent. In all other regions, there was an increase, from 0.4 percent in the West to 3.1 percent in the Northeast. Diagnostic Categories In May 2025, diabetes mellitus entered the top five telehealth diagnostic categories in the Midwest and West for the first time in 2025. In the Midwest, this diagnostic category entered in fifth position, displacing overweight and obesity; in the West, it entered in fourth position, displacing acute respiratory diseases and infections, which fell to the fifth rank, supplanting sleep disorders. In the South, diabetes fell off the list from fifth position, replaced by encounter for examination. In May, mental health conditions remained in first position nationally and in every region, though the percentage of patients with a telehealth claim for this diagnostic category decreased nationally and in all regions. Nationally, it fell from 63.0 percent in April to 62.1 percent in May. Urban versus Rural In May 2025, as in April, telehealth utilization was higher in urban than rural areas nationally and in every region.2 Nationally, 14.5 percent of patients in urban areas had a telehealth claim, compared to 7.5 percent in rural areas. The largest difference occurred in the West, where the percentage of urban patients using telehealth (18.8 percent) was 2.4 times the percentage of rural patients (7.9 percent). The smallest difference was found in the Northeast, where the percentage of patients in urban areas using telehealth (16.7 percent) was 1.5 times the percentage of patients in rural areas using telehealth (11.4 percent). Age Distribution In May 2025, as in April, the age groups 19-30 and 31-40 accounted for the largest percentages of patients with a telehealth claim nationally and in every region. Nationally in May, the age group 31-40 (22.8 percent) displaced the age group 19-30 (22.4 percent) as the age group with the largest percentage of patients having a telehealth claim. The same shift happened in the Northeast and South, though in the Midwest and West, the age group 19-30 still had the largest percentage of patients with a telehealth claim. Nationally and in every region, the age groups 0-9 and 65 and older accounted for the smallest shares (less than 10 percent each) of patients with a telehealth claim. Procedure Categories In May 2025, psychotherapy services and procedures, and established patient office or other outpatient services (including those for mental health conditions), were, as in April, the top two procedure categories nationally and in every region. The order of the two varied: In May, established patient office or other outpatient services ranked first nationally (at 47.7 percent of patients with a telehealth claim) and in the South and West, while psychotherapy services and procedures ranked first in the Midwest and Northeast. In April, established patient office or other outpatient services ranked second nationally (47.48 percent), while psychotherapy services and procedures (47.49 percent) ranked first. About the Monthly Telehealth Regional Tracker Launched in May 2020 as a free service, the Monthly Telehealth Regional Tracker uses FAIR Health data to track how telehealth is evolving from month to month. An interactive map of the four US census regions allows the user to view an infographic on telehealth in a specific month in the nation as a whole or in individual regions. Each year, the infographic introduces varied views into telehealth utilization. In this sixth iteration of the Monthly Telehealth Regional Tracker, each infographic shows month-to-month changes in telehealth utilization, both through telehealth's percentage of medical claim lines and percent of patients with a telehealth claim; that month's top five diagnostic categories; top five procedure categories; age distribution, which captures the percentage of patients within each age group with a telehealth claim; and urban versus rural telehealth usage. For the Monthly Telehealth Regional Tracker, click here. Follow us on X @FAIRHealth About FAIR Health FAIR Health is a national, independent nonprofit organization that qualifies as a public charity under section 501(c)(3) of the federal tax code. It is dedicated to bringing transparency to healthcare costs and health insurance information through data products, consumer resources and health systems research support. FAIR Health possesses the nation's largest collection of commercial healthcare claims data, which includes over 51 billion claim records and is growing at a rate of about 4 billion claim records a year. FAIR Health licenses its commercial data and data products—including benchmark modules, data visualizations, custom analytics and market indices—to commercial insurers and self-insurers, employers, providers, hospitals and healthcare systems, government agencies, researchers and others. Certified by the Centers for Medicare & Medicaid Services (CMS) as a national Qualified Entity, FAIR Health also receives data representing the experience of all individuals enrolled in traditional Medicare Parts A, B and D, which accounts for a separate collection of over 51 billion claim records; FAIR Health includes among the commercial claims data in its database, data on Medicare Advantage enrollees. FAIR Health can produce insightful analytic reports and data products based on combined Medicare and commercial claims data for government, providers, payors and other authorized users. FAIR Health's systems for processing and storing protected health information have earned HITRUST CSF certification and achieved AICPA SOC 2 Type 2 compliance by meeting the rigorous data security requirements of these standards. As a testament to the reliability and objectivity of FAIR Health data, the data have been incorporated in statutes and regulations around the country and designated as the official, neutral data source for a variety of state health programs, including workers' compensation and personal injury protection (PIP) programs. FAIR Health data serve as an official reference point in support of certain state balance billing laws that protect consumers against bills for surprise out-of-network and emergency services. FAIR Health also uses its database to power a free consumer website available in English and Spanish, which enables consumers to estimate and plan for their healthcare expenditures and offers a rich educational platform on health insurance. An English/Spanish mobile app offers the same educational platform in a concise format and links to the cost estimation tools. The website has been honored by the White House Summit on Smart Disclosure, the Agency for Healthcare Research and Quality (AHRQ), URAC, the eHealthcare Leadership Awards, appPicker, Employee Benefit News and Kiplinger's Personal Finance. For more information on FAIR Health, visit Contact:Rachel KentExecutive Director of Communications and MarketingFAIR Health646-396-0795rkent@ 1 A claim line is an individual service or procedure listed on an insurance claim.2 Each telehealth service was attributed to a rural/urban designation in a region based on the patient's medical service area, which FAIR Health determines based on the unique geographical pattern of services utilized by the patient.
Malaysian Reserve
2 hours ago
- Malaysian Reserve
REMAX Sells Master Franchise Rights in Malaysia, Expanding the Global Brand's Presence in Southeast Asia
New region driven by REMAX value proposition and trusted brand reputation. DENVER, Aug. 15, 2025 /PRNewswire/ — REMAX® proudly announces the brand's expansion with the signing of a regional franchise agreement in Malaysia. REMAX Malaysia joins a worldwide network with a presence in more than 110 countries and territories – a global footprint unmatched by any other real estate brand. The newly launched operation is led by experienced entrepreneur and real estate expert Kelly Ang, who cited the REMAX reputation, international network and community-driven approach as key reasons for purchasing the rights to REMAX Malaysia in the thriving Southeast Asian nation with a population of 35 million. 'Having worked in the real estate industry for over two decades, I've developed a deep understanding of market dynamics and consumer needs,' said Ang. 'Our experience, paired with the robust support system at REMAX, positions us to thrive in this exciting new chapter.' Based in Kuala Lumpur, the capital and largest city, REMAX Malaysia plans to grow its roster of Registered Estate Agents (REAs) and Real Estate Negotiators (RENs) to support clients and communities across the country – all while leaning into the brand's global resources, elite education and productivity-driven culture. The region's official launch has already garnered accolades, including the 2025 International Prestige Brand Award—presented by the Asia Excellence Entrepreneur Federation (AEEF)—recognizing the professionalism of REMAX Malaysia's affiliates and strength of the REMAX brand. 'REMAX and REMAX Malaysia share a commitment to integrity and client service,' Ang added. 'We're eager to deliver an elevated experience to both the professionals joining our team and the consumers we serve.' Shawna Gilbert, REMAX Senior Vice President of Global and Commercial, praised Ang's vision and leadership saying, 'Kelly Ang is a driven, strategic professional with the expertise to establish REMAX Malaysia as a benchmark for real estate excellence throughout the country.' To further support its international network, REMAX recently launched MAXRefer, an AI-powered global referral platform. MAXReferSM simplifies every step of the referral process – from smart agent matching to secure tracking and built-in referral fee payments – making it easier than ever for REMAX agents to collaborate across borders. 'People recognize REMAX all around the world – and it's the community of outstanding professionals who make REMAX the trusted, productive, and unstoppable brand it is,' said Gilbert. 'It's our priority to provide global affiliates with the best resources, tools, and support they need to build their businesses.' This launch follows two international milestones: the sale of master franchise rights in Côte d'Ivoire, expanding the REMAX brand's presence across Western Africa, and the opening of REMAX Premier in Bahrain, located in the dynamic Seef District of Manama. These developments reflect the brand's strategic focus on global growth and its commitment to connecting local markets with international buyers and investors. About the REMAX NetworkAs one of the leading global real estate franchisors, RE/MAX, LLC is a subsidiary of RE/MAX Holdings (NYSE: RMAX) with more than 145,000 agents in nearly 9,000 offices and a presence in more than 110 countries and territories. Nobody in the world sells more real estate than REMAX, as measured by residential transaction sides. REMAX was founded in 1973 by Dave and Gail Liniger, with an innovative, entrepreneurial culture affording its agents and franchisees the flexibility to operate their businesses with great independence. REMAX agents have lived, worked and served in their local communities for decades, raising millions of dollars every year for Children's Miracle Network Hospitals® and other charities. To learn more about REMAX, to search home listings or find an agent in your community, please visit For the latest news about REMAX, please visit
Malaysian Reserve
3 hours ago
- Malaysian Reserve
GDS Wealth Management Named to Inc. 5000 List for Second Consecutive Year
DALLAS, Aug. 15, 2025 /PRNewswire/ — GDS Wealth Management, a premier financial advisory firm serving individuals and families across the nation, is proud to announce its inclusion on the Inc. 5000 list of fastest-growing private companies in the U.S. for the second year in a row. This recognition by Inc. Magazine, a benchmark of entrepreneurial success for over four decades, underscores GDS Wealth Management's unwavering commitment to excellence, results, and hard work. The firm's continued growth is a testament to its mission: to help people live better lives, not only for the clients it serves, but also for the dedicated professionals who power its success. 'According to Harvard Business Review, the average person works 90,000 hours in their lifetime,' said Glen D. Smith, founder, CEO, and CIO at GDS Wealth Management. 'At GDS Wealth Management, we believe those hours should yield more than just financial security; they should lead to fulfillment, freedom, and peace of mind. Being recognized on the Inc. 5000 list for the second consecutive year is both humbling and affirming. I'm incredibly proud of the exceptional team that pours their energy, expertise, and passion into serving our clients with unwavering dedication and excellence'. With a team of passionate, highly skilled advisers, GDS Wealth Management is committed to delivering high quality service tailored to the unique needs of individuals and families. The firm's holistic approach to wealth management includes investment strategy, estate planning, tax optimization, and legacy building, anchored by a deep understanding of each client's goals and values. As the firm grows, it continues to uphold its core values and strives to deliver positive outcomes for clients. Click here to learn more about the Inc. 5000 ranking methodology, or for the complete results of the Inc. 5000, including company profiles and an interactive database that can be sorted by industry, location, and other criteria. Ready to elevate your financial future with confidence and clarity? Partner with a GDS Wealth Management adviser and experience personalized, goal-driven guidance tailored to your unique goals. Call us at (469) 212-8072 or visit to schedule your complementary financial consultation today. Inclusion on the Inc. 5000 list is not indicative of GDS Wealth Management's future performance or client experience. No compensation was provided for this recognition. Visit for methodology details.
